AbbVie Pins Hopes on Hepatitis C Treatment
An FDA approval of AbbVie's hepatitis C regimen “will be a welcome breath of fresh air for a company that hasn't really produced anything for 10 years,” said Bernard Munos, a pharmaceutical research-and-development consultant who previously worked at ...
Wall Street Journal - Wed, 17 Dec 2014 14:24

Cost of Hepatitis C drug means major state Medicaid spend
ALBANY—New York state's Medicaid program spent $193.2 million during the first six months of 2014 on Sovaldi, the controversial Hepatitis C drug that carries an $84,000-per-patient price tag. Sovaldi cost Medicaid more than any other drug in the ...
Capital New York - Wed, 17 Dec 2014 03:26

High price has VA rationing new hepatitis C drug
Sen. Bernie Sanders (I-Vt.) used one of his last hearings as chairman of the Senate Veterans Affairs Committee to review how VA has had to ration a break-through medicine that cures hepatitis C, a liver virus infecting 174,000 veterans, because a ...
Daily Press - Thu, 18 Dec 2014 07:11

Draft report finds Gilead's $95K hepatitis C drug is worth it — but unaffordable
San Francisco Business Times (blog) - Wed, 17 Dec 2014 07:42

Employer Heads to Court for Class-Action Suit Over Cost of Hep C Drug Sovaldi
Healthline - Mon, 15 Dec 2014 17:18

Philly's Transit System Sues Gilead for "Price-Gouging" Price of Hepatitis C Drug - Tue, 16 Dec 2014 11:18

Lawsuit Claims Hep C Drugmaker is Price-Gouging
The National Law Journal (registration) - Mon, 15 Dec 2014 02:30

There Is Still Time To Join The Gilead Bandwagon (GILD)
Seeking Alpha - Mon, 15 Dec 2014 12:48

One million people with hepatitis C in the US at high priority for treatment
An estimated 813,000 people with diagnosed hepatitis C in the US have undergone liver disease staging and meet the 'highest' or 'high' priority criteria for immediate treatment, according to an analysis presented at the American Association for the ...
aidsmap - Thu, 18 Dec 2014 00:37

Preventing hepatitis C patients from being lost in the health-care system
Medical Xpress - Thu, 18 Dec 2014 06:37

Hepatitis C does not cause mental impairment in HIV patients
Clinical Advisor - Thu, 18 Dec 2014 08:52

Hepatitis C Doesn't Cause Mental Impairment in HIV Patients
Pharmacy Times - Wed, 17 Dec 2014 10:00

Battle In Hepatitis C Market: Bristol-Myers Squibb Needs To Speed Up
Hepatitis C is a blood-born diseases which affects an estimated 3.2 million people in the U.S., most of who will or have developed chronic infection. The overall market is likely to grow at a rapid pace and we believe that Gilead Sciences will continue ...
Trefis - Thu, 18 Dec 2014 09:48

Treatments for hepatitis C are always improving
Q: My 56-year-old sister has hepatitis C. She contracted the virus from a blood transfusion in the 1980s. It is the genotype 4 (north African) strain. It was discovered about 12 years ago, and, at that time, she had a biopsy that didn't show any ...
Columbus Dispatch - Sun, 14 Dec 2014 20:18

Wishing, hoping, planning as AbbVie's hep C do-or-die moment nears
As 2014 winds down, and Gilead Sciences keeps winding up hep C sales by the billion, AbbVie waits, vibrating with anticipation. Its three-drug cocktail is up for FDA approval any day now, and the Illinois-based company is ready to challenge Gilead for ...
FiercePharma - Thu, 18 Dec 2014 07:00

Expensive new treatment for hepatitis C patients
It's been two months since the FDA approved Harvoni, Gilead Sciences' newest cure for hepatitis C. The treatment for Harvoni consists of taking one pill a day for 12 weeks while experiencing little to no side effects. As convenient as the treatment ...
Long Island Report - Wed, 17 Dec 2014 15:26

1  2  3  4  5  6  7  8    ->

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014